Comparing Moolec Science (MLEC) and Its Competitors

Moolec Science (NASDAQ:MLEC) is one of 497 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Moolec Science to similar businesses based on the strength of its analyst recommendations, institutional ownership, dividends, profitability, earnings, valuation and risk.

Analyst Ratings

This is a summary of recent ratings for Moolec Science and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moolec Science	0	0	1	0	3.00
Moolec Science Competitors	1018	2929	7380	119	2.58

Moolec Science currently has a consensus price target of $6.00, indicating a potential upside of 552.17%. As a group, “Biotechnology” companies have a potential upside of 25.09%. Given Moolec Science’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Moolec Science is more favorable than its peers.

Profitability

This table compares Moolec Science and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moolec Science	-129.97%	-93.88%	-33.37%
Moolec Science Competitors	-6,960.64%	-101.02%	-26.44%

Institutional & Insider Ownership

0.1% of Moolec Science shares are owned by institutional investors. Comparatively, 33.8% of shares of all “Biotechnology” companies are owned by institutional investors. 19.9% of Moolec Science shares are owned by insiders. Comparatively, 20.2% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Moolec Science has a beta of -0.54, suggesting that its share price is 154% less volatile than the S&P 500. Comparatively, Moolec Science’s peers have a beta of 1.22, suggesting that their average share price is 22% more volatile than the S&P 500.

Earnings and Valuation

This table compares Moolec Science and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Moolec Science	$5.63 million	-$7.31 million	-4.60
Moolec Science Competitors	$1.56 billion	$44.75 million	16.74

Moolec Science’s peers have higher revenue and earnings than Moolec Science. Moolec Science is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Moolec Science peers beat Moolec Science on 8 of the 13 factors compared.

Moolec Science Company Profile

Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.